CoronaryAtlas logo
CoronaryAtlas
ASCVD Risk Atlas
← Back to table
A

Lipoprotein(a)

Lipids & LipoproteinsLab test / biomarkerrisknon modifiablegenetic-causal
84
evidence score

Also known as: Lipoprotein(a) [Lp(a)] levels > or =30 mg/dL, Lipoprotein(a) level, Lp(a) levels, Lp(a) lipoprotein level, lipoprotein (a), lipoprotein a, lipoprotein[a], lp(a), lpa

PREVENT status

Not a PREVENT input variable.

Causal support

genetic causal candidate

Score components
lit volume: 21.7meta-analyses: 17.6trials: 15genetic: 20MR bonus:
Associated genes
LPA

References (147)

6 meta-analyses / systematic reviews

Clinical trials (55)

NCTTitleStatusTypeInterventions
NCT07613294A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Lepodisiran to Investigate the Effect on Coronary Plaque in Adults With Elevated Lp(a) Who Have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular EventRECRUITINGINTERVENTIONALLepodisiran, Placebo
NCT07327840A Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate Efficacy and Safety of Kylo-11 in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)RECRUITINGINTERVENTIONALKylo-11 or matched placebo
NCT07157774A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Muvalaplin on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) Who Have Had a Prior Atherosclerotic Cardiovascular Event or Are at Risk for a First Atherosclerotic Cardiovascular EventRECRUITINGINTERVENTIONALMuvalaplin, Placebo
NCT0601406024 Versus 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stent in Patients With Elevated Lipoprotein(a) Levels: A Prospective, Multicenter, Double-Blind, Placebo-Controlled Randomized TrialRECRUITINGINTERVENTIONAL24 Months DAPT, 12 Months DAPT
NCT06980428A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4954 Following Single and Multiple Ascending Dose Administration to Healthy Participants With or Without Elevated Lp(a) Levels, and Participants With DyslipidemiaRECRUITINGINTERVENTIONALAZD4954, Placebo
NCT06875973A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVDRECRUITINGINTERVENTIONALPelacarsen (TQJ230)
NCT06813911A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Atherosclerotic Cardiovascular Disease (ASCVD), and Elevated LDL-C and Lp(a)RECRUITINGINTERVENTIONALPelacarsen, Placebo, Inclisiran
NCT06496243A Phase 2 Study to Evaluate the Effect of Obicetrapib Alone and in Combination With Evolocumab (Repatha®) on Lipoprotein (a) in Patients With Mild Dyslipidemia: The VINCENT StudyRECRUITINGINTERVENTIONALobicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks
NCT05646381A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis [Lp(a)FRONTIERS CAVS]RECRUITINGINTERVENTIONALPelacarsen (TQJ230) 80mg, Matching placebo
NCT07198009Modulation of Bioactive Lipids in Lipid Disorders: a Pilot Study of 2-HOBA Supplementation in Individuals With Elevated Lipoprotein(a)NOT YET RECRUITINGINTERVENTIONAL2-HOBA (Hobamine)
NCT06411860A Randomized, Placebo- and Positive-controlled, Crossover Study to Assess the Effect of Olpasiran (AMG 890) on QT/QTc Intervals in Healthy SubjectsCOMPLETEDINTERVENTIONALPlacebo, Olpasiran, Moxifloxacin
NCT06267560A Randomized Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Pelacarsen (TQJ230) in US Black/African American & Hispanic Patient Populations With Elevated Lp(a) and Established Atherosclerotic Cardiovascular DiseaseCOMPLETEDINTERVENTIONALTQJ230, Placebo
NCT05581303A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)ACTIVE NOT RECRUITINGINTERVENTIONALPlacebo, Olpasiran
NCT05563246KRAKEN: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Once-Daily LY3473329 in Adults With Elevated Lipoprotein(a) at High Risk for Cardiovascular EventsCOMPLETEDINTERVENTIONALLY3473329, Placebo
NCT05489614A Phase I, Open-label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Subjects With Normal Renal Function and Subjects With Various Degrees of Renal ImpairmentCOMPLETEDINTERVENTIONALOlpasiran
NCT04023552A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With Established Cardiovascular DiseaseACTIVE NOT RECRUITINGINTERVENTIONALTQJ230, Placebo
NCT04005573Assessing the Combined Effect of Omega-3 Fatty Acid and Vitamin D3 on Lipid Profile Levels and Oxidized Low Density Lipoprotein: a Randomized Controlled Trial in Males and Females With Vitamin D DeficiencyCOMPLETEDINTERVENTIONALVD3, omega 3- FA, VD3 and omega- 3FA
NCT03887520Multi-center Cross-sectional Epidemiological Study to Characterize the Prevalence and Distribution of Lipoprotein(a) Levels Among Patients With Established Cardiovascular DiseaseCOMPLETEDINTERVENTIONALBlood draw for Lp(a)
NCT03626662A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a)COMPLETEDINTERVENTIONALAMG 890, Placebo
NCT03473223A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary SyndromeCOMPLETEDINTERVENTIONALApolipoprotein A-I [human] (apoA-I), Placebo
NCT03070782A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) Administered Subcutaneously to Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease (CVD)COMPLETEDINTERVENTIONALISIS 681257, Placebo
NCT02781675Effects of a Modified High-fat Mediterranean Dietary Pattern on Lipoprotein and Inflammatory Markers of CVD Risk in AdultsCOMPLETEDINTERVENTIONALDietary Intervention
NCT02802904Multicountry Studies on the Effect of Positional Distribution of Fatty Acids at Triglyceride Backbone on Serum Lipids, Lipoprotein(a) and LDL-subclasses in Healthy Malaysian VolunteersCOMPLETEDINTERVENTIONALDiet: Palm olein IV64, Diet: Cocoa butter, Diet: Virgin olive oil
NCT02843906Cognitive, Morphological and Neurobiological Progressive Aspects in Bipolar Disorders in the Elderly: Toward to a Neurodegenerescence Detection?UNKNOWNINTERVENTIONALLombar Punction, Magnetic Resonance Imaging (MRI), Positron-Emission Tomography (TEP) /(FDG)
NCT02160899A Randomized, Double Blind, Placebo-Controlled, Dose Titration, Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 494372 Administered Subcutaneously to Patients With High Lipoprotein(a)COMPLETEDINTERVENTIONALISIS-APO(a)Rx, Placebo
NCT01895387Replacing With Whole Grains and Legumes Reduces Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Activities in Plasma and Peripheral Blood Mononuclear Cells in Patients With Prediabetes or Newly Diagnosed Type 2 DiabetesCOMPLETEDINTERVENTIONALDietary intervention-whole grains and legumes, Dietary intervention-Refined rice
NCT01321034Effect of Niacin in the Lipoprotein (a) Concentration With Regard to Apolipoprotein (a) Size and Baseline Lipoprotein (a) Concentration.COMPLETEDINTERVENTIONALNiacin/Laropiprant
NCT01064934Randomized Controlled Trial of Efficacy and Safety of Lipid Apheresis for the Prevention of Cardiovasc. Events in Patients With Progr. Cardiovasc. Disease, Lp(a)≥ 60 mg/dl and LDL-C <130 mg/dl on Maximally Tolerated Lipid-lowering TherapyWITHDRAWNINTERVENTIONALLipid apheresis, Standard care
NCT02133807A 72-week, Prospective, Parallel-group, Partially Blinded, Controlled Phase IIIb Study Evaluating the Impact of Specific Lp(a) Apheresis on Atherosclerotic Disease Burden in Coronary Heart Disease Patients With High Lipoprotein(a) Level.COMPLETEDINTERVENTIONALSpecific Lp(a) apheresis
NCT00728910Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility StudyCOMPLETEDINTERVENTIONALAtorvastatin, ABT335, ER Niacin
NCT00268996An International, Multicenter, Randomized, Placebo-controlled, Parallel-group, 1 Year Treatment, Integrated Biomarkers and Imaging Study in Subjects With Angiographically Documented Coronary Heart Disease (CHD) to Examine the Effects of the Novel Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor SB-480848 on Intermediate Cardiovascular Endpoints, Patient Safety and TolerabilityCOMPLETEDINTERVENTIONALSB-480848, SB-480848 matching placebo
NCT07508007Lp(a)CCELERATE: Impact of Implementation Strategies on Lp(a) Testing in Secondary Care SettingsRECRUITINGOBSERVATIONAL
NCT06995183Improved Assessment of Cardiovascular Risk Through Imaging in Relatives Identified By Lipoprotein(a) Cascade ScreeningRECRUITINGOBSERVATIONAL
NCT06858332Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in RussiaRECRUITINGOBSERVATIONALAtorvastatin, Simvastatin, Rozuvastatin
NCT06126367Assessment of Lipoprotein(a) and Endogenous Fibrinolysis in Atherosclerotic Cardiovascular Disease/Aortic Valve DiseaseRECRUITINGOBSERVATIONALThrombotic assessment, Measurement of Lp(a)
NCT07577609Artificial Intelligence-assisted CT for Risk Stratification in COronary Artery Disease to PreveNt Future Coronary Events and Improve OutcomesRECRUITINGOBSERVATIONAL
NCT07197242Assessment of Lipoprotein(a) in Patients Undergoing Elective Percutaneous Coronary Revascularization: Implications for Cardiovascular Risk StratificationNOT YET RECRUITINGOBSERVATIONAL
NCT07594392Clinical Assessment and Targeted Imaging to Characterize High-Risk Atherosclerotic Cardiovascular Disease of Survivors in the St. Jude Lifetime Cohort (SJLIFE)NOT YET RECRUITINGOBSERVATIONALCoronary Artery Calcium Scan, Carotid Artery Ultrasound, Lipoprotein(a) Measurement
NCT07141628Etude de l'hyperlipoprotéinémie A Comme Marqueur de Risque Cardio-vasculaire Chez Les Patients Atteints de Maladie rénale Chronique au Stade 4NOT YET RECRUITINGOBSERVATIONALlipoprotein A level dosing
NCT07184034Assessment of the Correlation Between Lipoprotein (a) Levels and Coronary Artery Findings on Multislice Computed TomographyNOT YET RECRUITINGOBSERVATIONAL
NCT07390604Case Series : Management of Elevated Lipoprotein(a) Using Double-Filtration Plasmapheresis (DFPP) in Hemodialysis Patients With Chronic Kidney Disease Clinical and Biological Outcomes in Patients at Cardiovascular and Thromboembolic RiskCOMPLETEDOBSERVATIONAL
NCT06648915Association of Lipoprotein(a) With Progression of Degenerative Aortic Valve Stenosis: Propensity-matched StudyACTIVE NOT RECRUITINGOBSERVATIONALLipoprotein(a)
NCT06626659Lipoprotein (a) and Vascular Regenerative Cell ContentCOMPLETEDOBSERVATIONAL
NCT07209631Is Lipoprotein-a Just a Lipid Marker or a Predictor for the Severity of Coronary Lesions in Aortic Valve Sclerosis Patients?COMPLETEDOBSERVATIONALSerum Lipoprotein-a level
NCT06304415Investigating The Prevalence and Clinical Significance of Elevated Lipoprotein(a) Blood Levels in Hospital StaffACTIVE NOT RECRUITINGOBSERVATIONAL
NCT06297239Argentine Registry for the Study of Lipoprotein aUNKNOWNOBSERVATIONAL
NCT06316466Lipoprotein a is an Independent Risk Factor for Overall Survival in Patients With Pancreatic Cancer: a Propensity Score Matching AnalysisUNKNOWNOBSERVATIONALLp(a)
NCT04239352Levels of Inflammatory and Cardiovascular Risk Markers in Preeclamptic Patients; New Biomarkers: Pentraxin 3 & Lipoprotein-associated Phospholipase A2COMPLETEDOBSERVATIONALPentraxin 3 ; new biomarker, Lipoprotein-associated phospholipase A2 ; new biomarker
NCT03220971Theranostic Translation Applications Against Viral, Metabolic Liver Diseases and Hepatic Oncogenesis: Lipoprotein and Apolipoproteins at a CrossroadUNKNOWNOBSERVATIONALlipoprotein and apolipoproteins
NCT02976818Relationships Between Lipoprotein(a) Levels and Aortic Valve Calcification in Patients With Heterozygous Familial HypercholesterolemiaCOMPLETEDOBSERVATIONAL
NCT02791802A European Multicenter Study on the Effect of Lipoprotein(a) Elimination by Lipoprotein Apheresis on Cardiovascular OutcomesUNKNOWNOBSERVATIONAL
NCT03041480The Association Between Periodontal Status, Serum Lipid Levels and Lipoprotein Associated Lipophosphase A2(Lp-PLA2) in Chronic Periodontitis Subjects and Healthy Controls: A Case Control StudyCOMPLETEDOBSERVATIONALserum lipid levels and Lp-PLA2
NCT01753232Non-interventional Study: Safety and Efficacy of the DALI LDL-adsorber and MONET-lipoprotein FilterCOMPLETEDOBSERVATIONALDALI-adsorber, MONET-Lipoprotein filter
NCT00853775Regulation of Lipoprotein(a) Metabolism in Humans With Reference to EthnicityCOMPLETEDOBSERVATIONALNo intervention, observational study
NCT07079267Olpasiran Expanded Access ProgramAVAILABLEEXPANDED_ACCESSOlpasiran

Genetic associations (258)

showing top 80 by significance
VariantGene(s)TraitpOR/βStudy
LPA1e-221361.7 ln nmol/L increaseGCST011087
LPA1e-193801.02095 nmol/l decreaseGCST012232
LPA1e-192151.4083 unit increaseGCST90019513
LPA1e-10320.26 mmol/L increaseGCST90501340
LPA1e-9290.24 mmol/L increaseGCST90501336
LPA1e-8910.24 % decreaseGCST90501331
LPA1e-8140.23 % increaseGCST90501341
LPA1e-8130.22 mmol/L increaseGCST90501337
LPA1e-8080.22 mmol/L increaseGCST90501338
LPA1e-7890.22 mmol/L increaseGCST90501334
LPA1e-7500.22 % decreaseGCST90501335
LPA1e-7220.22 % decreaseGCST90501333
LPA1e-7100.21 mmol/L increaseGCST90501330
LPA1e-6490.19 nm increaseGCST90501292
LPA1e-6320.2 mmol/L increaseGCST90501332
LPA1e-5860.19 % decreaseGCST90501309
LPA1e-5780.19 mmol/L increaseGCST90501316
LPA1e-5220.18 % decreaseGCST90501307
LPA1e-5180.18 mmol/L increaseGCST90501293
LPA1e-5050.17 % decreaseGCST90501161
LPA1e-4990.18 mmol/L increaseGCST90501312
LPA1e-4710.17 mmol/L increaseGCST90501314
LPA1e-4700.17 mmol/L increaseGCST90501168
LPA1e-4590.17 mmol/L increaseGCST90501313
LPA1e-4390.17 % decreaseGCST90501159
LPA1e-4360.16 mmol/L increaseGCST90501282
LPA1e-4320.17 mmol/L increaseGCST90501310
LPA1e-4200.16 mmol/L increaseGCST90501256
LPA1e-4120.15 ratio increaseGCST90501273
LPA1e-39632.43 mg/dL increaseGCST004398
LPA1e-3690.15 % decreaseGCST90501251
LPA1e-367—GCST90239655
LPA1e-3660.15 mmol/L increaseGCST90501164
LPA1e-3640.15 mmol/L increaseGCST90501165
LPA1e-3570.15 % increaseGCST90501317
LPA1e-3370.14 mmol/L increaseGCST90501166
LPA1e-3210.135534 unit decreaseGCST90002412
LPA1e-3200.281537 unit increaseGCST90093050
LPA1e-3120.14 mmol/L increaseGCST90501289
LPA1e-3090.13 % decreaseGCST90501199
LPA1e-3050.14 % decreaseGCST90501255
LPA1e-3050.14 mmol/L increaseGCST90501306
LPA1e-3040.14 mmol/L increaseGCST90501162
LPA1e-303—GCST90239673
LPA1e-2950.14 mmol/L increaseGCST90501216
LPA, LPAL21e-2890.24159032 unit decreaseGCST90468081
LPA1e-2840.14 mmol/L increaseGCST90501218
LPA1e-2830.277545 unit decreaseGCST90093041
LPA1e-2820.113763 unit increaseGCST90239658
LPA1e-2810.14 % increaseGCST90501249
LPA, PLG1e-2810.134443 % increaseGCST90500518
LPA1e-2790.0500926 unit decreaseGCST90828065
LPA1e-2790.14 % increaseGCST90501197
LPA1e-2770.261294 unit increaseGCST90093046
LPA1e-2740.13 % increaseGCST90501257
LPA, PLG1e-2740.34183052 unit decreaseGCST90470257
LPA1e-2650.266534 unit decreaseGCST90093045
LPA1e-2620.397064 % increaseGCST90498146
LPA1e-2611.43GCST90837544
LPA1e-2581.43GCST90837546
LPA1e-2560.265252 unit increaseGCST90093051
LPA1e-2460.187148 mmol/L decreaseGCST90499740
LPA1e-2430.12 mmol/L increaseGCST90501268
LPA1e-241—GCST90321120
LPA1e-2400.101838 unit decreaseGCST90828061
LPA1e-2390.242419 unit increaseGCST90093047
LPA1e-2390.380979 % increaseGCST90498119
rs10455872LPAcoronary atherosclerosis1e-2340.2816 unit decreaseGCST90475936
LPA1e-2340.2816 unit decreaseGCST90475936
LPA1e-2330.23877 unit increaseGCST90093048
LPA1e-2330.12 mmol/L increaseGCST90501270
LPA1e-2310.238256 unit increaseGCST90093044
LPA1e-2250.234177 unit decreaseGCST90093019
LPA1e-2210.100603 unit increaseGCST90239676
LPA1e-2210.12 mmol/L increaseGCST90501304
LPA1e-220—GCST90239667
LPA1e-2200.247126 unit decreaseGCST90093043
LPA1e-2190.12 % decreaseGCST90501231
LPA1e-2191.47245E-4 unit decreaseGCST90828062
LPA1e-2190.12 mmol/L increaseGCST90501277